Clinical trial
Effect of AC2993 (Synthetic Exendin-4) Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin
NCT00082381 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of AC2993 (Synthetic Exendin-4) Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin
- Lead sponsor
- AstraZeneca
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 30, 2003
- Completion date
- July 31, 2008
- Enrollment
- 551 (actual)
- Sites
- 91
Conditions
As the registry lists them; a condition with its own page is linked.